Radioimmunotherapy for Indolent B-Cell Non-Hodgkin Lymphoma in Relapsed, Refractory and Transformed Disease

被引：0

作者：

Otto J. Visser

Lars R. Perk

Josée M. Zijlstra

Guus A.M.S. van Dongen

Peter C. Huijgens

Arjan A. van de Loosdrecht

机构：

[1] VU University Medical Center,Department of Hematology

[2] VU University Medical Center,Department of Otolaryngology/Head and Neck Surgery

来源：

BioDrugs | 2006年 / 20卷

关键词：

Autologous Stem Cell Transplantation; Bone Marrow Involvement; Bone Marrow Infiltration; Tositumomab; Ibritumomab Tiuxetan;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Radioimmunotherapy (RIT) is a new treatment modality that combines the benefits of radiotherapy and immunotherapy. In RIT, a radionuclide is coupled to a monoclonal antibody, directed against an antigen expressed on tumor cells. Recently, RIT has been introduced targeting the CD20 surface antigen, which is expressed on nearly all B-cell non-Hodgkin lymphomas (NHL).

引用

页码：201 / 207

页数：6

共 50 条

[21] Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
Kang, Hye J.
Lee, Seung S.
Kim, Kyeong M.
Choi, Tae H.
Cheon, Gi J.
Kim, Won S.
Suh, Cheolwon
Yang, Sung H.
Lim, Sang M.
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 136 - +
[22] Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes
Davies, Andrew
[J]. EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (05) : 581 - 593
[23] Radioimmunotherapy with 90Y Ibritumomab Tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Palumbo, B.
Sabalich, I.
Falcinelli, F.
Capponi, M.
Martelli, M.
Palumbo, R.
Sinzinger, H.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
[24] RADIOIMMUNOTHERAPY IN THE PATIENT WITH B-CELL NON-HODGKIN'S LYMPHOMA
Fernandez Natalia, Garcia
Cuellar Angeles, Flores
Santiago Maria del Rosario, Mora
Perez Cristina, Gonzalez
[J]. ATENCION FARMACEUTICA, 2012, 14 (01): : 34 - +
[25] The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma
Witzig, TE
[J]. SEMINARS IN ONCOLOGY, 2000, 27 (06) : 74 - 78
[26] Biweekly Bendamustine Monotherapy for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma and Mantle Cell Lymphoma: A Rabbit-14 Trial
Igarashi, Tadahiko
Wakita, Hisashi
Tsujimura, Hideki
Aotsuka, Nobuyuki
Masuda, Shinichi
Utsu, Yoshikazu
Murata, Naoya
Irisawa, Hiroyuki
Tsukasaki, Kunihiro
Itoh, Kuniaki
[J]. BLOOD, 2016, 128 (22)
[27] Improved Outcome of Relapsed or Refractory Pediatric B-Cell Non-Hodgkin Lymphoma in Japan
Osumi, Tomoo
Mori, Tetsuya
Fujita, Naoto
Saito, Akiko M.
Nakazawa, Atsuko
Tsurusawa, Masahito
Kobayashi, Ryoji
[J]. BLOOD, 2015, 126 (23)
[28] Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma
Galanina, Natalie
Jasielec, Jagoda
Peace, David
Smith, Sonali M.
Nabhan, Chadi
[J]. LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 752 - 753
[29] Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma
Meredith, Ruby F.
Knox, Susan J.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (02): : S15 - S22
[30] Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Graf, Solomon A.
Lynch, Ryan C.
Coffey, David G.
Shadman, Mazyar
Kanan, Sandra
Libby, Edward N., III
Warren, Edus H.
Godwin, Colin
Gooley, Ted
Fromm, Jonathan R.
Gopal, Ajay K.
[J]. BLOOD, 2018, 132

← 1 2 3 4 5 →